Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See
full details
.
I Agree
×
Join today and have your say! It’s FREE!
Join Now
Sign In
Become a member today, It's free!
We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.
Join Today
or
Sign in with existing account
Privacy Policy
|
Disclaimer
Sign In
Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Remember me
Forgot Password?
Sign In
or
Sign Up
Privacy Policy
|
Disclaimer
Please Try Again
{{ error }}
Send my password
Submit
Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.
Become a member today, It's free!
We will not release or resell your information to third parties without your permission.
Linking with Facebook:
Stockhouse membership requires an email address which must be shared by Facebook.
By default, joining or signing in using your Facebook account will work and the email address will be shared by Facebook automatically.
If you change your Facebook permissions to restrict Stockhouse from receiving your email while joining or signing in to Stockhouse then it will fail.
Please do not modify the permission settings during sign-in.
Sign in with Facebook
Return to Signup Options
Home
Community
Bullboards
Blogs
Groups
Messages
Markets
Stocks
TSX
TSXV
CSE
Cboe Canada
NASDAQ
NYSE
NYSE American
Cryptocurrency
Currencies
Market Movers
Bonds
News
Featured News
Trending News
Canadian Press Releases
US Press Releases
Video
Editorial
Thematic Insights
Independent Reports
Interviews
Buzz on the Bullboards
Portfolio
Watchlist
Portfolio
Showcase Companies
DealRoom
Quote
|
Bullboard
|
News
|
Opinion
|
Profile
|
Peers
|
Filings
|
Financials
|
Options
|
Price History
|
Ratios
|
Ownership
|
Insiders
|
Valuation
Bullboard - Stock Discussion Forum
Crescita Therapeutics Inc
T.CTX
Alternate Symbol(s):
CRRTF
Healthcare
Biotechnology
Crescita Therapeutics Inc. is a commercial dermatology company with in-house research and development (R&D) and manufacturing capabilities. It offers a portfolio of science-based non-prescription skincare products and early to commercial stage prescription products. It operates in three segments: Commercial Skincare, Licensing and Royalties, and Manufacturing and Services. The Commercial...
Skincare segment manufactures and sells branded non-prescription skincare products for the Canadian and international markets. It also commercializes Pliaglis, NCTF Boost 135 HA, ART FILLER, and Obagi Medical in Canada. The Licensing and Royalties segment engaged in licensing the intellectual property related to Pliaglis or its transdermal delivery technologies. Manufacturing and Services segment engaged in the sale of topical products manufactured to client specifications under the Company’s contract development and manufacturing organization infrastructure, and product development services.
see more
Join the community and start posting on the bullboards today. It's free.
You are already a member! Please enter your password to sign in.
Remember me
Forgot password?
Back
Submit
By providing my email, I consent to receiving messages from Stockhouse.
Create a portfolio watchlist today. It's free.
You are already a member! Please enter your password to sign in.
Remember me
Forgot password?
Back
Submit
By providing my email, I consent to receiving messages from Stockhouse.
Add To Watchlist
Bullboard (TSX:CTX)
New Post
View:
Posts & Comments
Threaded Posts
Prev
1
2
Next
(1711)
•••
lscfa
X
Post by
lscfa
on Mar 18, 2025 1:06pm
Q4 results
Qtr ending Skincare Licensing Manufacturing Total rev ebitda
...more
(10)
•••
Rahil1234
X
Post by
Rahil1234
on Feb 11, 2025 8:10pm
Crescita's Comeback: Strategic Growth and Key Acquisitions
https://substack.com/home/post/p-156966361
(1787)
•••
Possibleidiot01
X
Post by
Possibleidiot01
on Oct 23, 2024 3:17pm
Mathieu Martin - Stocks and Stones
#5 - Crescita Therapeutics (TSX: CTX) Those who’ve been following Crescita for a significant amount of time know that the stock has been a value trap. Although the business has
...more
(1787)
•••
Possibleidiot01
X
Post by
Possibleidiot01
on Sep 05, 2024 5:22pm
addition to latest Atrium takeover report
https://mcusercontent.com/4bc421505c66d079778a0d0be/files/c84f1943-b069-7c62-f72d-87f54a469d3b/20240905_Atrium_Takeouts_Part_3.02.pdf Small-Cap Takeouts Thematic Research 4September 5, 2024 Crescita
...more
(1787)
•••
Possibleidiot01
X
Post by
Possibleidiot01
on Aug 09, 2024 5:43pm
Mathieu Martin - Stocks and Stones
Crescita Therapeutics (TSX: CTX) is firing on all cylinders. In the span of a week, CTX announced a distribution agreement for a new medical aesthetic product, a new long-term manufacturing deal for
...more
(1711)
•••
lscfa
X
Post by
lscfa
on Jul 22, 2024 9:50am
$10M 4 yr contract
Crescita Secures Contract Manufacturing Revenue of $US10 Million Over 4 Years LAVAL, Quebec--(BUSINESS WIRE)--July 22, 2024--Crescita Therapeutics Inc. (TSX: CTX and OTC US: CRRTF) (“Crescita” or
...more
(1711)
•••
lscfa
X
Post by
lscfa
on Jul 19, 2024 8:57am
5 yr contract
Crescita Therapeutics Inc. (TSX: CTX and OTC US: CRRTF) (“Crescita” or the “Company”), a growth-oriented, innovation-driven Canadian commercial dermatology company with in-house R&D and
...more
(1711)
•••
lscfa
X
Post by
lscfa
on Mar 15, 2024 12:37am
Q4 on sedar
Skincare biz growing. Looking for new customers for their contract manufacturing biz where the plant has a capacity of $25 mil/yr. Skincare
...more
(1711)
•••
lscfa
X
Comment by
lscfa
on Mar 15, 2024 12:32am
RE:NCAV = $0.637/share
Cash/share = $0.47 and cash flow positive biz
(24)
•••
Stonksonlyup90
X
Post by
Stonksonlyup90
on Mar 13, 2024 8:40pm
NCAV = $0.637/share
After the release of financials this week I'm seeing NCAV at $0.637/share. Despite struggles in their manufacturing segment this does seem grossly undervalued here. What are the chances the
...more
(3)
•••
daydream1
X
Comment by
daydream1
on Nov 09, 2023 9:34am
RE:RE:RE:RE:Net-Net Stock - cheap stock
Management knew a while ago the Taro deal was done and dead. There was no proactive steps taken by them at all. This company is done, cash will only evaporates over time. The only outcome is for them
...more
(13)
•••
drewmumaw
X
Comment by
drewmumaw
on Nov 08, 2023 10:58am
RE:RE:RE:Net-Net Stock - cheap stock
So much for the down side being limited. Disastrous Q3 results released today.
(7)
•••
stef1234
X
Comment by
stef1234
on Oct 04, 2023 7:54pm
RE:RE:Net-Net Stock - cheap stock
I agree totally with your comments Drewmumaw. You nailed down the issue with this company. As Warren Buffet said it many times, we can't as a passive investor replace a management team
...more
(13)
•••
drewmumaw
X
Comment by
drewmumaw
on Sep 29, 2023 3:30pm
RE:Net-Net Stock - cheap stock
"...I believe the downside is very limited." Agreed. But the upside appears very limited too. Current management can’t seem to find a way to grow the business. Their compensation seems way
...more
(1711)
•••
lscfa
X
Comment by
lscfa
on Aug 27, 2023 2:40pm
RE:Net-Net Stock - cheap stock
working capital $0.75/sh
Prev
1
2
Next
Thank You
Your Report has been submitted.
Report Abusive Content
×
Close
Sign up to get access
You are already a member! Please enter your password to sign in.
Remember me
Forgot password?
Back
Submit
By providing my email, I consent to receiving messages from Stockhouse.
Market Update
{{currentVideo.title}}
{{currentVideo.relativeTime}}
{{previousButtonTitle}}
{{nextButtonTitle}}
A daily snapshot of everything
from market open to close.
{{currentVideo.companyName}}
{{currentVideo.intervieweeName}}
{{currentVideo.intervieweeTitle}}
{{currentVideo.headline}}
{{currentVideo.link1Text}}
{{currentVideo.link2Text}}
< Previous
{{moreVideoText}}
Next >
Featured News Links
Healthcare and Clinical Stage Drug Development Company Acquires NoBrainer Imaging Centers